Human palatine tonsil-derived mesenchymal stem cells (TMSCs) are known to be a new source of progenitor cells. Using waste tissue after tonsillectomy as a cell provider can be the biggest benefit of TMSCs, compared with other stem cells. The purpose of this study was to investigate tenogenic differentiation of TMSCs and to access the differential effects of transforming growth factor beta 3 (TGF-β3) on the tenogenesis of TMSCs. Human tonsil was obtained after tonsillectomy. Using a cytometric analysis, we were able to find that the TMSCs had typical mesenchymal stem cell markers: positive for CD73, CD90, and CD105, and negative for CD14, CD34, and CD45. Using TGF-β3, the expressions of tenocyte-specific genes and proteins, such as collagen type 1 (COL1), tenomodulin (TNMD), and scleraxis (SCX), were measured by a quantitative polymerase chain reaction (PCR), immunofluorescence staining, immunohistochemistry and Western blot analyses. Quantitative PCR assay showed that TGF-β3 significantly increased the expressions of tenocyte lineage marker genes, including COL1, TNMD, and SCX, at a 3-day treatment, compared with control. However, these increases were not found at long-term exposures (7 or 10 days), except that TNMD expression was maintained at 50 ng/mL at a 7-day exposure to TGF-β3. Like genes, the protein expression levels of COL1, TNMD, and SCX were also induced in TGF-β3-treated TMSCs in a 3-day treatment, which were maintained for 10 days, as evidenced by immunofluorescence staining, immunohistochemistry and Western blot analyses. This study demonstrated that TMSCs in tenogenic stimulation with TGF-β3 have a high tenogenic differentiation potential.
INTRODUCTION
Rotator cuff tears are the main cause of severe pain and physical disability of non-traumatic upper limb in populations over 50 years old. The incidence of rotator cuff tears increases with aging in humans, therefore they can be considered as a natural age-related degenerative disease [1] . Similarly, the frequently encountered Achilles tendon rupture also occurs most commonly in the elderly population [1] . Direct surgical repair is generally recommended for the completely ruptured tendon [2, 3] . However, wound healing after the surgery to repair a ruptured tendon is still challenging [4] [5] [6] . One of reasons that may contribute to poor healing of tendon is a limitation of self-healing potential of the scar tissue on the repaired tendon [7, 8] . Tendon healing process with scarring results in the formation of adhesion and feeling of weakness in the affected area [9, 10] .
For these reasons, tissue engineering with mesenchymal stem cells (MSCs) have been used for tendon repair in both in vivo and in vitro [11] [12] [13] . Several previous studies reported that marrow-derived and adipose tissue-derived MSCs showed significant improvement of biomechanical properties of injured tendon in animal model [11, 12] . However, these stem cells are obtained through invasive procedures, and there is usually a lack of adequate numbers for clinical use [14] . Human embryonic stem cells (hESCs) are another source of pluripotent cells, and have attracted enormous attention for its therapeutic potential. However, transplantation of hESCs is complicated by teratoma formation [15] .
Human palatine tonsil-derived mesenchymal stem cells (TMSCs) represented a new source of progenitor cells [16] . Like other stem cells, these cells showed multilineage differentiation po- , Ha Yeong Kim 1, 3 , Inho Jo 1, 3 *, Sang-Jin Shin 2, 3 tential including adipogenesis, osteogenesis, and chondrogenesis [17] . Using waste tissue after tonsillectomy as a cell provider can be the biggest benefit of TMSCs, compared with other stem cells. In addition, a previous study has reported that TMSCs have a good potential for clinical banking of stem cells [16] . TMSCs have been on the spotlight as a source of stem cells for future therapeutic use [16] [17] [18] [19] [20] [21] [22] [23] . Although TMSCs have represented multilineage differentiation potential, studies were lacking regarding the tenogenic differentiation of TMSCs.
The purpose of this study was to investigate tenogenic differentiation of TMSCs and to access the differential effects of transforming growth factor beta 3 (TGF-β3) on the tenogenesis of TMSCs.
MATERIALS AND METHODS

TMSC isolation, culture and differentiation
This experimental study was approved by the institutional review board (ECT-11-53-02) of Ewha Womans University Medical Center. Informed consent was obtained from all the patients' legal guardians. Tonsils were obtained from children (4 to 10 years old) undergoing tonsillectomy. The tissue was minced and digested in Dulbecco' s modified Eagle' s medium (DMEM) (Welgene, Daegu, Korea) containing 210 U/mL collagenase type I (Invitrogen, Grand Island, NY, USA) and 10 μg/mL DNase I (Sigma, St. Louis, MO, USA) for 30 min at 37°C. Following filtration through a wire mesh, the cells were washed twice in DMEM containing 20% fetal bovine serum (FBS), and then once with 10% FBS-DMEM. Mononuclear cells were obtained by Ficoll-Paque Plus (GE Healthcare, Buckinghamshire, UK) density gradient centrifugation of digested tonsil tissues. Cells were plated and cultured in 150 cm 2 cell culture flasks, in DMEM containing 10% FBS and antibiotics (50 μg/mL streptomycin and 50 IU/mL penicillin) (Gibco, Grand Island, NY, USA). After 48 h, the non-adherent cells were removed and the adherent cells were expanded for 2 weeks.
Cells were passaged by using 0.05% trypsin-EDTA (Gibco) every 3-4 days, at 80-90% confluency. Cells were used for experiments at passage 3-4. To induce differentiation, cells were treated for 3, 7, and 10 days with TGF-β3 (20 ng/mL and 50 ng/ mL), or with vehicle control. Multiple studies have shown that TGF-β3 induces tenogenic differentiation of in vitro culture of MSCs [24, 25] . All cells were harvested after 3, 7, and 10 days for further experiments. During this time, the medium was changed every 2-3 days, and supplemented with fresh TGF-β3.
Immunochemistry analysis
The cells were fixed in -20°C methanol, and permeabilized for 30 sec with absolute acetone at -20°C. The endogenous peroxidase activity was quenched with methanol and 3% H2O2. Immunohistochemistry analysis was performed using the Vectastain ABC kit (Vector Laboratories, Burlingame, CA, USA). The cells were first incubated with the appropriate primary antibodies directed against collagen type 1 (COL1) (Abcam, Cam- bridge, MA, USA), tenomodulin (TNMD) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and scleraxis (SCX) (Abcam, Combridge, MA, USA) (all at 1:500 dilution) overnight at 4°C, after which they were reacted with a biotinylated secondary linking antibody and a streptavidin-peroxidase complex for 1 h. The final color product was developed using 3, 3'-diaminobenzidine chromogen (DAKO, Carpinteria, CA, USA). Images were analyzed using an Olympus BX41 microscope (Olympus, Center Valley, PA, USA) at 400 magnification.
Immunofluorescence assay
For immunofluorescence staining assay, the endogenous peroxidase activity was quenched with 3% hydrogen peroxide (Sigma) in methanol for 5 min. Non-specific binding was blocked with 10% normal goat serum diluted in DPBS for 30 min at room temperature. All cells were stained antibodies against using COL1, SCX, and TNMD (all at 1:100 dilution) overnight at 4°C, and then reacted with secondary anti-rabbit IgG for 2 h and incubated with 4' , 6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis, MO, USA) overnight at 4°C. The stained cells were analyzed using Zeiss microscope (LSM 510 Meta) (Carl Zeiss, Oberkochen, Germany) at 3400 magnification.
Flow cytometry analysis
Flow cytometry analysis was used to characterize the phenotypes of the TMSCs. At least 50000 cells (in 100 μL PBS containing 0.5% BSA and 0.01% NaN3) were incubated for 30 min at 4°C with fluorescein isothiocyanate-labeled antibodies against human CD34, CD45, CD90, CD105 (BD Biosciences, San Jose, CA, USA), phycoerythrin-labeled antibodies against human CD14, CD73 (BD Biosciences, San Jose, CA, USA), or the respective isotype controls (BD Biosciences, San Jose, CA, USA). Labeled cells were analyzed by flow cytometry using FACS Caliber flow cytometer and the Cell Quest Pro software (BD Biosciences, San Jose, CA, USA)
Quantitative real-time PCR (qRT-PCR) assay
Total RNA was extracted using TRIzol (Invitrogen, Grand Island, NY, USA). RNA concentrations were measured in quartz cuvette. Two micrograms of total RNA was reverse-transcribed using the transcriptor first strand cDNA Synthesis kit (Roche Applied Science, Mannheim, Germany). Messenger RNA (mRNA) expression was estimated by real-time polymerase chain reaction (PCR) with FastStart SYBR Green Master (Roche Applied Science) using StepOnePlus (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions.
Western blot analysis
Cells treated with vehicle or TGF-β3 (20 ng/mL and 50 ng/ mL) were washed with cold PBS, and the total proteins were extracted with a mixture of lysis buffer and protease inhibitor (GenDEPOT, Houston, TX, USA). The protein lysate (30 μg) Figure 2 . Effects of TGF-β3 on human TMSCs differentiation toward tenocyte lineage. TMSCs were treated for 3, 7, and 10 days with various doses (20 ng/mL and 50 ng/mL) of TGF-β3, or with vehicle control. mRNA levels were determined by qRT-PCR assay and normalized against vehicle control for a 3-day treatment. The results showed tendon markers were increased at early time point after TGF-β3 stimulation. The expression levels of (A) COL1, (B) TNMD, and (C) SCX in TMSCs. Data represent the mean±SD of three independent experiments (*p<0.05, **p<0.01, and ***p<0.001). TGF-β3: transforming growth factor beta 3, TMSCs: tonsil-derived mesenchymal stem cells, mRNA: messenger RNA. qRT-PCR: quantitative real-time polymerase chain reaction, COL1: collagen type 1, TNMD: tenomodulin, SCX: scleraxis. was loaded on 10% SDS-PAGE, followed by transfer to nitrocellulose membranes (Invitrogen, Grand Island, NY, USA). The blots were then blocked with 5% nonfat dry milk in Tris-buffered saline containing Tween 20 (TBST) for 1 h at room temperature, after which they were incubated overnight at 4°C with anti-COL1, anti-TMND, or anti-GAPDH antibody. After washing with TBST, the blots were incubated with goat anti-mouse or anti-rabbit HRP-conjugated secondary antibody and the bands were revealed with enhanced chemiluminescence reagents (Amersham Biosciences, Piscataway, NJ, USA).
Statistical analysis
All data are presented as mean±standard deviation. Statistical significance among different concentrations and time points were analyzed by one-way analysis of variance (ANOVA), followed by Tukey's multiple comparison test using GraphPad Prism software ver. 6 (GraphPad Software Inc., La Jolla, CA, USA) (*p<0.05, **p<0.01 and ***p<0.001).
RESULTS
Immunophenotype characterization of TMSCs
Human MSCs have shown specific expression profiles of surface immunophenotypic markers of MSCs. According to the International Society for Cellular Therapy, hematopoietic markers such as CD14, CD34, and CD45 should be negative and MSC markers including CD73, CD90, and CD105 should be positively expressed. In order to analyze whether TMSCs express negatively for CD14, CD34, and CD45 and positively for CD73, CD90, and CD105, we performed flow cytometry. As shown in Figure 1 , immunophenotypic surface marker analysis of TMSCs revealed that TMSCs expressed a typical MSCs. TMSCs did not express CD14, CD34, and CD45, which are positively present on hematopoietic stem cells and leukocytes, while staining for CD73, CD90, and CD105 were positive in TMSCs.
TGF-β3 stimulates the expression of tenogenic genes in TMSCs
TGF-β3 was used to differentiate TMSCs into tenocytes, and performed qRT-PCR for detection of genes of COL1, TNMD, and SCX. TMSCs were treated for 3, 7, and 10 days with TGF-β3 at 20 ng/mL and 50 ng/mL, or with vehicle control. All mRNA levels were determined by qRT-PCR and normalized against vehicle control for a 3 day-treatment. Exposure of TGF-β3 to TMSCs resulted in an increase in the expression of COL1, TNMD, and SCX, usually at 3 day. However, when TMSCs were induced with TGF-β3 for 7 and 10 days, these genes were not increased significantly, except TNMD (Fig. 2) ; only the expression of TNMD was significantly induced at 50 ng/mL of TGF-β3 on 7 (Fig. 2B) . These results indicate that TGF-β3 upregulates the tendon-associated genes at early time point.
TGF-β3 increases the tenogenic proteins in TMSCs
Immunofluorescence and immunocytochemistry assays for the detection of tenocyte-related proteins were also performed. The immunofluorescence staining analysis exhibited COL1, TNMD, and SCX in green, and nuclei of cells were stained in blue by DAPI. TGF-β3-stimulated TMSCs expressed evidently higher levels of COL1, TNMD, and SCX, as compared with the control group. The expression of COL1 was upregulated by TGF-β3 as early as day 3, but the level of COL1 expression was independent of increase of concentration (Fig. 3A) . TNMD and SCX presented a maximum increase at 50 ng/mL in 7 day treatment ( Fig. 3B and C) . Immunohistochemistry analysis also confirmed the results of the tenogenic gene expression analysis. COL1 expression was increased via the stimulation of TGF-β3; unlike immunofluorescence data, immunohistochemistry showed significant levels of COL1 expression in 10 day culture of control TMSCs, which were further increased in TGF-β3-treated cells (Fig. 4A) . The level of TNMD and SCX proteins were also significantly increased, depending on the times of exposure to TGF-β3 ( Fig. 4B and C) . Taken together, our data supported that TGF-β3 is capable of inducing tenogenic related proteins. Western blotting analysis also confirmed the increase of expression of COL1 and TNMD by the stimulation of TGF-β3. Both the proteins were significantly increased from 3 day (Fig. 5) . Collectively, the results indicate again that TGF-β3 is capable of inducing the expression of tendon-related marker proteins in TMSCs.
DISCUSSION
TMSCs have represented multilineage differentiation potential, including osteogenesis, adipogenesis, and chondrogenesis. Therefore, we hypothesized that TMSCs also had a potential of tenogenic differentiation. To the best of our knowledge, this is the first report that demonstrates that TMSCs have the potential of tenogenic differentiation. In the present study, genes predominantly expressed in tenocytes were observed in the differentiated cells procured from TMSCs stimulated with TGF-β3.
Although several human tissues, such as bone marrow and adipose tissue, have been used as a source of stem cell for tenogenesis, there were limitations, including a lack of adequate cell numbers and donor site morbidity [14] . Furthermore, donor age may also affect the differentiation potential of MSCs [26] [27] [28] . TMSCs showed stemness and the feasibility as a candidate for stem cell banking in future clinical use [16] . Because TMSCs displayed immunomodulatory effects, they can be also used as an allogenic source of MSCs in clinical fields [16] . In the United States, study of a national survey revealed that the tonsillectomy rate is 6.87 per 1000 children [29] . Among them, 68.7% of the patients were children less than 15 years old [30] . Because tonsil, which is a medical waste tissue after surgery, is generally harvested in young patients, it would be expected that a larger amount of cells for cryopreservation in a tissue bank, and better proliferative ability are advantageous in TMSCs as compared with MSCs from other cell sources. Moreover, TMSCs showed a shorter doubling time than bone marrow-derived MSCs [17] . Because TMSCs have multilineage differentiation potentials and advantages compared with other cell sources, it has been in the spotlight as a source of stem cells for future therapeutic use.
In the present study, anti-COL1, anti-SCX, and anti-TNMD antibodies were used to access the expression of tendon matrix proteins and the tenocytes themselves. These markers have been used to prove whether TMSCs were differentiated into tenocytes (Table 1) . Tenocytes are responsible for the production of extracellular components of the tendon, including COL1 and decorin [31, 32] . COL1 is the major constituent of the tendon, and decorin is the essential component which is a part of proteoglycans. SCX and TNMD have been reported as tenocyte lineage markers [33, 34] . Overexpression of SCX in MSCs, inter [35] . Because SCX is upregulated in response to the TGF-β3 [36] , here we hypothesized that the human TMSCs can be differentiated into tenocytes in response to TGF-β3 stimulation. In addition to TGF-β3, bone morphogenetic protein-12 (BMP-12) was also reported to be involved in tenogenic differentiation [37, 38] . Under our experimental conditions, however, treatment with BMP-12 was unlikely to be effective on tenogenic differentiation of TMSCs; it increased mRNA of only COL1, but not of TNMD and SCX (data not shown). Some of chondrogenic differentiation factors such as platelet rich plasma [39] and growth differentiation factor-5 [40] are also likely to mediate tenocytic differentiation because both chondrogenesis and tenogenesis are highly active and cooperative in particular during musculoskeletal tissue regeneration. However, whether these chondrogenic differentiation factors indeed mediate tenogenic differentiation of TMSCs warrants further investigations. Our results demonstrated that TMSCs showed differentiation potentials into tendon-like cells. On qRT-PCR assay, mRNA of COL1, SCX, and TNMD were increased on the 3rd stimulation day. Although expression levels of mRNA of each marker differed according to stimulation doses of TGF-β3, their expression levels decreased likewise after the 3rd day of stimulation. Following mRNA expression of markers, we also observed the increase of protein levels of each marker on immunofluorescence, immunohistochemistry and Western blot analyses. In the present study, however, the differentiated cells did not microscopically display any significant change in morphology. It was previously reported that hMSCs subjected to mechanical stretching tend to be oriented almost perpendicular to the direction of stretching [41] . Although chemical stimulation leads to the expression of tenogenic genes and proteins in differentiated cell from TMSCs, mechanical stimuli may be essential for functional tendon tissue engineering. Therefore, future studies will be needed to understand the specific mechanisms of mechanical control for tenogenic differentiation in TMSCs.
The potential use of TMSCs-derived tenocytes is diverse, and its applications are broad in the clinical field. TMSCs can allow for the mass production of stem cells as compared with MSCs from other cell sources, and can be stored in tissue banks. Namely, patients who had tendon injury or tendinopathy can undergo tenocyte implantation without stem cell harvest. This will also allow physicians to use stem cell therapy easily in patient with tendon injuries or tendinopathy. Nonetheless, treatment of tendon injury is still challenging [7, 8] . In rotator cuff tears, the rate of retears of the repaired tendon have varied from 11% to 94% [42] . In Achilles tendon rupture, adhesion around the tendon following surgical treatment may result in limited range of motion of the ankle joint [43] , although the re-rupture rate following surgical treatment is under 3% [44] . Using tenocytes from TMSCs in the treatment of partially injured tendon or tendinopathy may decrease the complications following the treatment. An animal study reported that implantation of tendon-derived stem cells on an injured tendon showed an improved tendon healing process, as compared with direct repair [45] . However, the study regarding scaffold for tendon should be performed before clinical trial using tenocytes from TMSCs. Several previous studies reported that scaffold improves tendon properties after tenocyte implantation. According to the types of scaffold, new treatments which can substitute surgical treatment are expected. Injectable stem cell therapeutics may be a candidate for nonsurgical treatment for partial tendon injury or tendinopathy such as partial rotator cuff tear or intractable lateral epicondylitis, using thermo-sensitive scaffold. Rigid type of scaffold may decrease surgical complications in patients with large tendon defect who require surgical repair of the tendon, such as massive rotator cuff tear and Achilles tendon rupture. Further studies regarding stem cell therapeutics for tendon injury or tendinopathy are required.
Some limitations of this study should be addressed. First, TMSCs were stimulated by chemical only in the present study. Tendons respond to mechanical forces by adapting their metabolism [41] . Furthermore, the mechanical stretching stimulates the MSCs to proliferate and differentiate into tenocytes [41, 46] Therefore, based on the present study, we believe that future studies, including mechanical stimulation to TMSCs, should be performed to establish the protocol of tenocyte differentiation from TMSCs. Second, only TGF-β3 was used as a stimulator to TMSCs. Several other proteins have showed the effects on tenocyte differentiation potency of MSCs [37, 38, 47] . Various approaches will be required in terms of chemical stimulators.
In conclusion, we demonstrated that tenocyte-like cells can be successfully differentiated from TMSCs under TGF-β3 stimulation. The differentiated tenocytes from TMSCs may be used in tendon tissue regenerative engineering for partial ruptured tendon without surgery in clinical trials.
